{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:50:11Z","timestamp":1768366211073,"version":"3.49.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s43440-025-00809-3","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:01:23Z","timestamp":1764745283000},"page":"292-302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Thiazolidine derivative (LPSF\/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2345-3363","authenticated-orcid":false,"given":"Andr\u00e9a","family":"Tavares Dantas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-4320","authenticated-orcid":false,"given":"Anderson","family":"Rodrigues de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-1076","authenticated-orcid":false,"given":"Marina","family":"Ferraz Cordeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-3501","authenticated-orcid":false,"given":"Priscilla Stela","family":"Santana de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-1065","authenticated-orcid":false,"given":"Jos\u00e9 Arion","family":"da Silva Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-8202","authenticated-orcid":false,"given":"Michelly Cristiny","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1883-6012","authenticated-orcid":false,"given":"Moacyr Jesus","family":"Barreto de Melo\u00a0R\u00eago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-6529","authenticated-orcid":false,"given":"Rafaela","family":"Silva Guimar\u00e3es Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-2683","authenticated-orcid":false,"given":"Marina","family":"Galdino da Rocha\u00a0Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-9939","authenticated-orcid":false,"given":"Angela Luzia","family":"Branco Pinto Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-0338","authenticated-orcid":false,"given":"Maira","family":"Galdino da Rocha\u00a0Pitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"809_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41584-022-00864-7","volume":"18","author":"D Fang","year":"2022","unstructured":"Fang D, Chen B, Lescoat A, Khanna D, Mu R. Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis. Nat Rev Rheumatol. 2022;18:683\u201393. https:\/\/doi.org\/10.1038\/s41584-022-00864-7.","journal-title":"Nat Rev Rheumatol"},{"key":"809_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","volume":"64","author":"ME Truchetet","year":"2023","unstructured":"Truchetet ME, Brembilla NC, Chizzolini C. Current concepts on the pathogenesis of systemic sclerosis. Clin Rev Allergy Immunol. 2023;64:262\u201383. https:\/\/doi.org\/10.1007\/s12016-021-08889-8.","journal-title":"Clin Rev Allergy Immunol"},{"key":"809_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1093\/rheumatology\/kez486","volume":"59","author":"VK Jaeger","year":"2020","unstructured":"Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Air\u00f2 P, et al. Racial differences in systemic sclerosis disease presentation: a European scleroderma trials and research group study. Rheumatology (Oxford). 2020;59:1684\u201394. https:\/\/doi.org\/10.1093\/rheumatology\/kez486.","journal-title":"Rheumatology (Oxford)"},{"key":"809_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3899\/jrheum.121089","volume":"40","author":"A Sulli","year":"2013","unstructured":"Sulli A, Ruaro B, Smith V, Pizzorni C, Zampogna G, Gallo M, et al. Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol. 2013;40:634\u20139. https:\/\/doi.org\/10.3899\/jrheum.121089.","journal-title":"J Rheumatol"},{"key":"809_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","volume":"19","author":"JE Pope","year":"2023","unstructured":"Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19:212\u201326. https:\/\/doi.org\/10.1038\/s41584-023-00909-5.","journal-title":"Nat Rev Rheumatol"},{"key":"809_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrrheum.2013.46","volume":"9","author":"CP Denton","year":"2013","unstructured":"Denton CP, Ong VH. Targeted therapies for systemic sclerosis. Nat Rev Rheumatol. 2013;9:451\u201364. https:\/\/doi.org\/10.1038\/nrrheum.2013.46.","journal-title":"Nat Rev Rheumatol"},{"key":"809_CR7","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.bmc.2013.01.029","volume":"21","author":"VS Jain","year":"2013","unstructured":"Jain VS, Vora DK, Ramaa CS. Thiazolidine-2,4-diones: progress towards multifarious applications. Bioorg Med Chem. 2013;21:1599\u2013620. https:\/\/doi.org\/10.1016\/j.bmc.2013.01.029.","journal-title":"Bioorg Med Chem"},{"key":"809_CR8","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.bmc.2015.03.071","volume":"23","author":"N Chadha","year":"2015","unstructured":"Chadha N, Bahia MS, Kaur M, Silakari O. Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions. Bioorg Med Chem. 2015;23:2953\u201374. https:\/\/doi.org\/10.1016\/j.bmc.2015.03.071.","journal-title":"Bioorg Med Chem"},{"key":"809_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13098-019-0432-z","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, Shen X. Effect of Rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Diabetol Metab Syndr. 2019;11:35. https:\/\/doi.org\/10.1186\/s13098-019-0432-z.","journal-title":"Diabetol Metab Syndr"},{"key":"809_CR10","doi-asserted-by":"publisher","unstructured":"da Rocha Junior LF, Dantas AT, Duarte ALBP, de Melo Rego MJB, Pitta I. da R, Pitta MG da R. PPAR\u03b3 Agonists in adaptive immunity: what do immune disorders and their models have to tell us? PPAR Res. 2013;2013:519724. https:\/\/doi.org\/10.1155\/2013\/519724.","DOI":"10.1155\/2013\/519724"},{"key":"809_CR11","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1084\/jem.20082771","volume":"206","author":"L Klotz","year":"2009","unstructured":"Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, et al. The nuclear receptor PPAR\u03b3 selectively inhibits Th17 differentiation in a T cell\u2013intrinsic fashion and suppresses CNS autoimmunity. J Exp Med. 2009;206:2079\u201389. https:\/\/doi.org\/10.1084\/jem.20082771.","journal-title":"J Exp Med"},{"key":"809_CR12","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00054725-200209000-00004","volume":"8","author":"LJ Saubermann","year":"2002","unstructured":"Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis. 2002;8:330\u20139. https:\/\/doi.org\/10.1097\/00054725-200209000-00004.","journal-title":"Inflamm Bowel Dis"},{"key":"809_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1124\/mol.64.5.1169","volume":"64","author":"SW Chung","year":"2003","unstructured":"Chung SW, Kang BY, Kim TS. Inhibition of interleukin-4 production in CD4 + T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol Pharmacol. 2003;64:1169\u201379. https:\/\/doi.org\/10.1124\/mol.64.5.1169.","journal-title":"Mol Pharmacol"},{"issue":"939","key":"809_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ajcn\/87.4.939","volume":"87","author":"R Marion-Letellier","year":"2008","unstructured":"Marion-Letellier R, Butler M, D\u00e9chelotte P, Playford RJ, Ghosh S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells\u2013potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr. 2008;87(939):48. https:\/\/doi.org\/10.1093\/ajcn\/87.4.939.","journal-title":"Am J Clin Nutr"},{"key":"809_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/aps.2008.15","volume":"30","author":"W Wang","year":"2009","unstructured":"Wang W, Zhang H, Jin Y, Zhu B, Chen N. PPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells. Acta Pharmacol Sin. 2009;30:107\u201312. https:\/\/doi.org\/10.1038\/aps.2008.15.","journal-title":"Acta Pharmacol Sin"},{"key":"809_CR16","doi-asserted-by":"publisher","first-page":"e79815","DOI":"10.1371\/journal.pone.0079815","volume":"8","author":"Y Lu","year":"2013","unstructured":"Lu Y, Zhou Q, Shi Y, Liu J, Zhong F, Hao X, et al. SUMOylation of PPAR\u03b3 by Rosiglitazone prevents LPS-induced NCoR degradation mediating down regulation of chemokines expression in renal proximal tubular cells. PLoS ONE. 2013;8:e79815. https:\/\/doi.org\/10.1371\/journal.pone.0079815.","journal-title":"PLoS ONE"},{"key":"809_CR17","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/1521-4141(2001010)31:10<2857::aid-immu2857>3.0.co;2-x","volume":"31","author":"P Gosset","year":"2001","unstructured":"Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, et al. Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol. 2001;31:2857\u201365. https:\/\/doi.org\/10.1002\/1521-4141(2001010)31:10%3C2857::aid-immu2857%3E3.0.co;2-x.","journal-title":"Eur J Immunol"},{"key":"809_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1365-2133.2010.09844.x","volume":"163","author":"A Antonelli","year":"2010","unstructured":"Antonelli A, Ferri C, Ferrari SM, Colaci M, Giuggioli D, Fallahi P. Induction of CXCL10 secretion by interferon-\u03b3 and tumour necrosis factor-\u03b1 and its Inhibition by peroxisome proliferator-activated receptor-\u03b3 agonists in cultured scleroderma fibroblasts. Br J Dermatol. 2010;163:650\u20131. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09844.x.","journal-title":"Br J Dermatol"},{"key":"809_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","volume":"50","author":"A Antonelli","year":"2010","unstructured":"Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, et al. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine. 2010;50:260\u20137. https:\/\/doi.org\/10.1016\/j.cyto.2010.01.009.","journal-title":"Cytokine"},{"key":"809_CR20","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.4049\/jimmunol.164.12.6503","volume":"164","author":"N Marx","year":"2000","unstructured":"Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503\u20138. https:\/\/doi.org\/10.4049\/jimmunol.164.12.6503.","journal-title":"J Immunol"},{"key":"809_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/08916934.2015.1054028","volume":"48","author":"AT Dantas","year":"2015","unstructured":"Dantas AT, Gon\u00e7alves SMC, Pereira MC, de Almeida AR, Marques CDL, de Rego MJB. Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29). Autoimmunity. 2015;48:429\u201333. https:\/\/doi.org\/10.3109\/08916934.2015.1054028.","journal-title":"Autoimmunity"},{"key":"809_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/art.10052","volume":"46","author":"JC Oates","year":"2002","unstructured":"Oates JC, Reilly CM, Crosby MB, Gilkeson GS. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. 2002;46:598\u2013605. https:\/\/doi.org\/10.1002\/art.10052.","journal-title":"Arthritis Rheum"},{"key":"809_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2337\/diabetes.53.1.200","volume":"53","author":"B Guo","year":"2004","unstructured":"Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes. 2004;53:200\u20138. https:\/\/doi.org\/10.2337\/diabetes.53.1.200.","journal-title":"Diabetes"},{"key":"809_CR24","doi-asserted-by":"publisher","first-page":"L891","DOI":"10.1152\/ajplung.00333.2007","volume":"294","author":"JE Milam","year":"2008","unstructured":"Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294:L891\u2013901. https:\/\/doi.org\/10.1152\/ajplung.00333.2007.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"809_CR25","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1165\/rcmb.2009-0006OC","volume":"41","author":"HE Ferguson","year":"2009","unstructured":"Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, et al. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol. 2009;41:722\u201330. https:\/\/doi.org\/10.1165\/rcmb.2009-0006OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"809_CR26","doi-asserted-by":"publisher","first-page":"e15909","DOI":"10.1371\/journal.pone.0015909","volume":"6","author":"AA Kulkarni","year":"2011","unstructured":"Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ. PPAR-\u03b3 ligands repress TGF\u03b2-induced myofibroblast differentiation by targeting the PI3K\/Akt pathway: implications for therapy of fibrosis. PLoS ONE. 2011;6:e15909. https:\/\/doi.org\/10.1371\/journal.pone.0015909.","journal-title":"PLoS ONE"},{"key":"809_CR27","doi-asserted-by":"publisher","unstructured":"Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr. 2010;91. https:\/\/doi.org\/10.3945\/ajcn.2009.28449E.:267S-272S.","DOI":"10.3945\/ajcn.2009.28449E"},{"key":"809_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","unstructured":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"809_CR29","doi-asserted-by":"publisher","unstructured":"R\u00eago MJB de M, Azoubel-Antunes A, Bezerra MB-CF, Pereira MC, Silva JC da, Lins TUL e, et al. Ability of two new thiazolidinediones to downregulate proinflammatory cytokines in peripheral blood mononuclear cells from children with asthma. Brazilian J Pharm Sci. 2018;54:1\u201310. https:\/\/doi.org\/10.1590\/s2175-97902018000300049.","DOI":"10.1590\/s2175-97902018000300049"},{"key":"809_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82410-1","volume":"11","author":"IA Guedes","year":"2021","unstructured":"Guedes IA, Barreto AMS, Marinho D, Krempser E, Kuenemann MA, Sperandio O, et al. New machine learning and physics-based scoring functions for drug discovery. Sci Rep. 2021;11:1\u201319. https:\/\/doi.org\/10.1038\/s41598-021-82410-1.","journal-title":"Sci Rep"},{"key":"809_CR31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ins.2014.08.002","volume":"289","author":"CS De Magalh\u00e3es","year":"2014","unstructured":"De Magalh\u00e3es CS, Almeida DM, Barbosa HJC, Dardenne LE. A dynamic Niching genetic algorithm strategy for Docking highly flexible ligands. Inf Sci (Ny). 2014;289:206\u201324. https:\/\/doi.org\/10.1016\/j.ins.2014.08.002.","journal-title":"Inf Sci (Ny)"},{"key":"809_CR32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.9b00905","author":"KB Santos","year":"2020","unstructured":"Santos KB, Guedes IA, Karl ALM, Dardenne LE. Highly flexible ligand docking: benchmarking of the DockThor program on the LEADS-PEP protein-peptide data set. J Chem Inf Model. 2020;60:667\u201383. https:\/\/doi.org\/10.1021\/acs.jcim.9b00905."},{"key":"809_CR33","doi-asserted-by":"publisher","unstructured":"Jang JY, Bae H, Lee YJ, Choi Y, Il, Kim H, Park SB et al. Structural basis for the enhanced anti-diabetic efficacy of Lobeglitazone on PPAR\u03b3. Sci Rep 2018:1\u201311. https:\/\/doi.org\/10.1038\/s41598-017-18274-1.","DOI":"10.1038\/s41598-017-18274-1"},{"key":"809_CR34","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbadis.2012.09.014","volume":"1832","author":"LA Borthwick","year":"2013","unstructured":"Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue fibrosis. Biochim Biophys Acta. 2013;1832:1049\u201360. https:\/\/doi.org\/10.1016\/j.bbadis.2012.09.014.","journal-title":"Biochim Biophys Acta"},{"key":"809_CR35","doi-asserted-by":"publisher","unstructured":"Shima Y. Cytokines involved in the pathogenesis of SSc and problems in the development of anti-cytokine therapy. Cells. 2021;10. https:\/\/doi.org\/10.3390\/cells10051104.","DOI":"10.3390\/cells10051104"},{"issue":"2","key":"809_CR36","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of Interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24(2):328\u201332.","journal-title":"J Rheumatol"},{"key":"809_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","volume":"27","author":"S Sato","year":"2001","unstructured":"Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci. 2001;27:140\u20136. https:\/\/doi.org\/10.1016\/S0923-1811(01)00128-1.","journal-title":"J Dermatol Sci"},{"key":"809_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1128\/CDLI.6.5.660-664.1999","volume":"6","author":"LI Sakkas","year":"1999","unstructured":"Sakkas LI, Tourtellotte C, Berney S, Myers AR, Platsoucas CD. Increased levels of alternatively spliced Interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol. 1999;6:660\u20134. https:\/\/doi.org\/10.1128\/CDLI.6.5.660-664.1999.","journal-title":"Clin Diagn Lab Immunol"},{"key":"809_CR39","doi-asserted-by":"publisher","first-page":"154799","DOI":"10.1016\/j.cyto.2019.154799","volume":"125","author":"G Gasparini","year":"2020","unstructured":"Gasparini G, Cozzani E, Parodi A. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine. 2020;125:154799. https:\/\/doi.org\/10.1016\/j.cyto.2019.154799.","journal-title":"Cytokine"},{"key":"809_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00011-015-0806-0","volume":"64","author":"XL Huang","year":"2015","unstructured":"Huang XL, Wang YJ, Yan JW, Wan YN, Chen B, Li BZ, et al. Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis. Inflamm Res. 2015;64:151\u20139. https:\/\/doi.org\/10.1007\/s00011-015-0806-0.","journal-title":"Inflamm Res"},{"key":"809_CR41","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","volume":"183","author":"F Fossiez","year":"1996","unstructured":"Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce Proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593\u2013603. https:\/\/doi.org\/10.1084\/jem.183.6.2593.","journal-title":"J Exp Med"},{"key":"809_CR42","doi-asserted-by":"publisher","unstructured":"Tuhy T, Hassoun PM, Bryant AJ. Clinical features of pulmonary arterial hypertension associated with systemic sclerosis 2023:18. https:\/\/doi.org\/10.3389\/fmed.2023.1264906.","DOI":"10.3389\/fmed.2023.1264906"},{"key":"809_CR43","doi-asserted-by":"publisher","first-page":"156534","DOI":"10.1016\/j.cyto.2024.156534","volume":"176","author":"N Seki","year":"2024","unstructured":"Seki N, Tsujimoto H, Tanemura S, Ishigaki S, Takei H. Cytokine Th17 \/ IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH. Cytokine. 2024;176:156534. https:\/\/doi.org\/10.1016\/j.cyto.2024.156534.","journal-title":"Cytokine"},{"key":"809_CR44","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/labinvest.2010.73","volume":"90","author":"SK Mathai","year":"2010","unstructured":"Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest. 2010;90:812\u201323. https:\/\/doi.org\/10.1038\/labinvest.2010.73.","journal-title":"Lab Invest"},{"key":"809_CR45","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/BF02247812","volume":"16","author":"EJ Kucharz","year":"1997","unstructured":"Kucharz EJ, Brzezinska-Wcislo L, Kotulska A, Gasiorowska-Kielkowska W, Gozdzik J. Elevated serum level of interleukin-10 in patients with systemic sclerosis. Clin Rheumatol. 1997;16:638\u20139. https:\/\/doi.org\/10.1007\/BF02247812.","journal-title":"Clin Rheumatol"},{"key":"809_CR46","doi-asserted-by":"publisher","first-page":"764641","DOI":"10.1155\/2015\/764641","volume":"2015","author":"E Sziksz","year":"2015","unstructured":"Sziksz E, Pap D, Lippai R, B\u00e9res NJ, Fekete A, Szab\u00f3 AJ, et al. Fibrosis related inflammatory mediators: role of the IL-10 cytokine family. Mediators Inflamm. 2015;2015:764641. https:\/\/doi.org\/10.1155\/2015\/764641.","journal-title":"Mediators Inflamm"},{"key":"809_CR47","doi-asserted-by":"publisher","first-page":"986199","DOI":"10.3389\/fphar.2022.986199","volume":"13","author":"R-H Guo","year":"2022","unstructured":"Guo R-H, Cheng H, Zhang X-Y, Yu Z, Wang G-H, Hao S-Y, et al. Changes in peripheral T-lymphocyte subsets and serum cytokines in patients with systemic sclerosis. Front Pharmacol. 2022;13:986199. https:\/\/doi.org\/10.3389\/fphar.2022.986199.","journal-title":"Front Pharmacol"},{"key":"809_CR48","doi-asserted-by":"publisher","first-page":"L341","DOI":"10.1152\/ajplung.00122.2010","volume":"300","author":"L Sun","year":"2011","unstructured":"Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2\/CCR2 axis. Am J Physiol Lung Cell Mol Physiol. 2011;300:L341\u201353. https:\/\/doi.org\/10.1152\/ajplung.00122.2010.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"809_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/bbrc.2001.4321","volume":"281","author":"T Yamamoto","year":"2001","unstructured":"Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun. 2001;281:200\u20135. https:\/\/doi.org\/10.1006\/bbrc.2001.4321.","journal-title":"Biochem Biophys Res Commun"},{"key":"809_CR50","doi-asserted-by":"publisher","first-page":"15220","DOI":"10.1074\/jbc.275.20.15220","volume":"275","author":"DJ Abraham","year":"2000","unstructured":"Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem. 2000;275:15220\u20135. https:\/\/doi.org\/10.1074\/jbc.275.20.15220.","journal-title":"J Biol Chem"},{"key":"809_CR51","doi-asserted-by":"publisher","first-page":"30226","DOI":"10.1074\/jbc.M005310200","volume":"275","author":"F Verrecchia","year":"2000","unstructured":"Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-alpha inhibits transforming growth factor-beta \/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem. 2000;275:30226\u201331. https:\/\/doi.org\/10.1074\/jbc.M005310200.","journal-title":"J Biol Chem"},{"key":"809_CR52","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.4049\/jimmunol.171.7.3855","volume":"171","author":"K Yamane","year":"2003","unstructured":"Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003;171:3855\u201362. https:\/\/doi.org\/10.4049\/jimmunol.171.7.3855.","journal-title":"J Immunol"},{"key":"809_CR53","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1002\/art.11129","volume":"48","author":"C Chizzolini","year":"2003","unstructured":"Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum. 2003;48:2593\u2013604. https:\/\/doi.org\/10.1002\/art.11129.","journal-title":"Arthritis Rheum"},{"key":"809_CR54","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/ard.2008.096123","volume":"68","author":"CP Denton","year":"2009","unstructured":"Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of Infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009;68:1433\u20139. https:\/\/doi.org\/10.1136\/ard.2008.096123.","journal-title":"Ann Rheum Dis"},{"key":"809_CR55","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1684\/ejd.2010.0946","volume":"20","author":"C Mattozzi","year":"2010","unstructured":"Mattozzi C, Richetta AG, Cantisani C, Giancristoforo S, D\u2019Epiro S, Gonzalez Serva A, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. Eur J Dermatol. 2010;20:400\u20131. https:\/\/doi.org\/10.1684\/ejd.2010.0946.","journal-title":"Eur J Dermatol"},{"key":"809_CR56","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s10165-011-0550-4","volume":"22","author":"J Ram\u00edrez","year":"2012","unstructured":"Ram\u00edrez J, Hern\u00e1ndez MV, Galve J, Ca\u00f1ete JD, Sanmart\u00ed R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol. 2012;22:602\u20134. https:\/\/doi.org\/10.1007\/s10165-011-0550-4.","journal-title":"Mod Rheumatol"},{"key":"809_CR57","first-page":"59","volume":"11","author":"FA Stewart","year":"2013","unstructured":"Stewart FA, Gavino ACP, Elewski BE. New side effect of TNF-alpha inhibitors: morphea. Skinmed. 2013;11:59\u201360.","journal-title":"Skinmed"},{"key":"809_CR58","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.37738","volume":"65","author":"T H\u00fcgle","year":"2013","unstructured":"H\u00fcgle T, O\u2019Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M, et al. Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum. 2013;65:481\u201391. https:\/\/doi.org\/10.1002\/art.37738.","journal-title":"Arthritis Rheum"},{"key":"809_CR59","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/00002281-200311000-00015","volume":"15","author":"SP Atamas","year":"2003","unstructured":"Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003;15:772\u20137. https:\/\/doi.org\/10.1097\/00002281-200311000-00015.","journal-title":"Curr Opin Rheumatol"},{"key":"809_CR60","doi-asserted-by":"publisher","unstructured":"Distler JH, Akhmetshina A, Schett G, Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatol. 2009;48:98\u2013103. https:\/\/doi.org\/10.1093\/rheumatology\/ken401.","DOI":"10.1093\/rheumatology\/ken401"},{"key":"809_CR61","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/art.40171","volume":"69","author":"M Wu","year":"2017","unstructured":"Wu M, Baron M, Pedroza C, Salazar GA, Ying J, Charles J, et al. CCL2 in the circulation predicts Long-Term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol (Hoboken NJ). 2017;69:1871\u20138. https:\/\/doi.org\/10.1002\/art.40171.","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"809_CR62","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/art.23591","volume":"58","author":"CE Vergunst","year":"2008","unstructured":"Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, van den Smith MD, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008;58:1931\u20139. https:\/\/doi.org\/10.1002\/art.23591.","journal-title":"Arthritis Rheum"},{"key":"809_CR63","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/art.21975","volume":"54","author":"JJ Haringman","year":"2006","unstructured":"Haringman JJ, Gerlag DM, Smeets TJM, van den Baeten D, Bresnihan B, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:2387\u201392. https:\/\/doi.org\/10.1002\/art.21975.","journal-title":"Arthritis Rheum"},{"key":"809_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1242\/jcs.108.1.311","volume":"108","author":"JR Dunlevy","year":"1995","unstructured":"Dunlevy JR, Couchman JR. Interleukin-8 induces motile behavior and loss of focal adhesions in primary fibroblasts. J Cell Sci. 1995;108:311\u201321. https:\/\/doi.org\/10.1242\/jcs.108.1.311.","journal-title":"J Cell Sci"},{"key":"809_CR65","first-page":"1524","volume":"30","author":"S Furuse","year":"2003","unstructured":"Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, et al. Serum concentrations of the CXC chemokines Interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol. 2003;30:1524\u20138.","journal-title":"J Rheumatol"},{"key":"809_CR66","first-page":"S46","volume":"29","author":"V Riccieri","year":"2011","unstructured":"Riccieri V, Stefanantoni K, Vasile M, Macr\u00ec V, Sciarra I, Iannace N, et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol. 2011;29:S46\u201352.","journal-title":"Clin Exp Rheumatol"},{"key":"809_CR67","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","volume":"34","author":"S Vettori","year":"2014","unstructured":"Vettori S, Cuomo G, Iudici M, D\u2019Abrosca V, Giacco V, Barra G, et al. Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels. J Clin Immunol. 2014;34:663\u20138. https:\/\/doi.org\/10.1007\/s10875-014-0037-0.","journal-title":"J Clin Immunol"},{"key":"809_CR68","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s10165-012-0795-6","volume":"23","author":"M Hasegawa","year":"2013","unstructured":"Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, et al. Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Mod Rheumatol. 2013;23:1076\u201384. https:\/\/doi.org\/10.1007\/s10165-012-0795-6.","journal-title":"Mod Rheumatol"},{"key":"809_CR69","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00296-008-0829-8","volume":"29","author":"P Coral-Alvarado","year":"2009","unstructured":"Coral-Alvarado P, Quintana G, Garces MF, Cepeda LA, Caminos JE, Rondon F, et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int. 2009;29:1017\u201324. https:\/\/doi.org\/10.1007\/s00296-008-0829-8.","journal-title":"Rheumatol Int"},{"key":"809_CR70","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/ard.2010.137349","volume":"70","author":"V Codullo","year":"2011","unstructured":"Codullo V, Baldwin HM, Singh MD, Fraser AR, Wilson C, Gilmour A, et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis. 2011;70:1115\u201321. https:\/\/doi.org\/10.1136\/ard.2010.137349.","journal-title":"Ann Rheum Dis"},{"key":"809_CR71","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1191\/0961203305lu2223oa","volume":"14","author":"A Consoli","year":"2005","unstructured":"Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus. 2005;14:794\u20137. https:\/\/doi.org\/10.1191\/0961203305lu2223oa.","journal-title":"Lupus"},{"key":"809_CR72","doi-asserted-by":"publisher","first-page":"100160","DOI":"10.1016\/j.ejmcr.2024.100160","volume":"11","author":"S Basak","year":"2024","unstructured":"Basak S, Murmu A, Matore BW, Roy PP, Singh J. Thiazolidinedione an auspicious scaffold as PPAR-\u03b3 agonist: its possible mechanism to manoeuvre against insulin resistant diabetes mellitus. Eur J Med Chem Rep. 2024;11:100160. https:\/\/doi.org\/10.1016\/j.ejmcr.2024.100160.","journal-title":"Eur J Med Chem Rep"},{"key":"809_CR73","doi-asserted-by":"publisher","unstructured":"Hinchcliff M, O\u2019Reilly S. Current and potential new targets in systemic sclerosis therapy: a new hope. Curr Rheumatol Rep. 2020;22. https:\/\/doi.org\/10.1007\/s11926-020-00918-3.","DOI":"10.1007\/s11926-020-00918-3"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00809-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00809-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:03:27Z","timestamp":1768341807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00809-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00809-3","relation":{"references":[{"id-type":"doi","id":"10.1021\/acs.jcim.9b00905","asserted-by":"subject"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee (Comit\u00ea de \u00c9tica em Pesquisa) of Universidade Federal de Pernambuco (CEP\/CCS\/UFPE 529\/11), according to the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants in the study provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}